Ilyang awaits approval for ilaprazole in Korea
Published: 2008-09-08 06:58:00
Updated: 2008-09-08 06:58:00
Ilyang Pharm is soon expecting to receive marketing approval for ilaprazole, a new investigational proton pump inhibitor, from the Korea Food and Drug Administration as the KFDA gave a nod on the safety and efficacy of the new drug after a stringent screening.
"Based on the pharmacokinetic pro...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
